Back to results
US 9,067,994 B2Granted
Anti-IL13 antibodies and uses thereof
AssigneeGenentech, Inc.
InventorsSek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeGenentech, Inc.
InventorsSek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
Estimating the term…
The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
A monoclonal anti-IL-13 antibody that binds specifically to human IL-13, wherein said antibody binds to the same epitope of human IL-13 as an antibody produced by hybridoma 228B/C-1 designated American Type Culture Collection (“ATCC”) accession number PTA-5657.
Dependencies are inferred from the claim text.